Allergan And Editas Medicine Announce Dosing Of First Patient In Landmark Phase 1/2 Clinical Trial Of CRISPR Medicine AGN-151587 (EDIT-101) For The Treatment Of LCA10

by bizlift | Mar 4, 2020 | Editas Press Releases, Portfolio News

Editas Medicine And Sandhill Therapeutics, Inc. Announce Collaboration To Develop Engineered Cell Medicines To Treat Cancer

by bizlift | Jan 13, 2020 | Editas Press Releases, Portfolio News

Editas Medicine Strengthens Executive Leadership Team To Support Long-Term Growth

by bizlift | Jan 9, 2020 | Editas Press Releases, Portfolio News

Editas Medicine Announces In Vivo Proof-Of-Concept Data For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia

by bizlift | Dec 9, 2019 | Editas Press Releases, Portfolio News

Editas Medicine and Celgene Corp Amend Existing Collaboration

by bizlift | Nov 12, 2019 | Editas Press Releases, Portfolio News

Editas Medicine Appoints Judith R. Abrams, M.D., as CMO

by bizlift | Oct 28, 2019 | Editas Press Releases, Portfolio News